



ASX & Media Release

Patrys Increases Capital Raising to \$4.6 million

Melbourne, Australia; May 21, 2018: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce that further to the Capital Raising announcement on 16 May 2018, the Company has increased the size of the share placement to \$4.6 million (before costs) due to additional demand from two strategic investors.

The single tranche placement will now consist of 135,294,117 new fully paid ordinary shares in Patrys at \$0.034 (3.4 cents) per share. The new shares will be issued under ASX Listing Rule 7.1 and 7.1A. The placement is expected to settle on Tuesday, 22 May 2018.

Somers and Partners Pty Ltd acted as lead manager to the Placement.

Funds raised will be used to accelerate the development of Patrys' Deoxymab platform, with a range of new pre-clinical studies planned to create shareholder value by supporting business development efforts, as well as corporate activities including insurance claim prosecution.

-Ends-

For further information, please contact:

Patrys Limited:
James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Patrys IR:
Ben Walsh
WE Buchan
P: +61 2 9237 2801
bwalsh@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.